Business
Ligand to Report Third Quarter Financial Results on November 9, 2021
EMERYVILLE, Calif.--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report financial results for the three and nine months ended
About this update from Ligand Pharmaceuticals Incorporated
[{"type":"text","content":" EMERYVILLE, Calif.--(BUSINESS WIRE)--\nLigand Pharmaceuticals Incorporated (NASDAQ: LGND) will report financial results for the three and nine months ended September 30, 2021 after the close of the U.S. financial markets on Tuesday, November 9, 2021 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg.\n\nConference Call and Webcast Information\n\n\n\nWhat:\n\n\n\n\nLigand conference call to discuss third quarter 2021 financial results and provide general business updates\n\n\n\n\n\n \n\n\n\n\n \n\n\n\n\n\nDate:\n\n\n\n\nTuesday, November 9, 2021\n\n\n\n\n\n \n\n\n\n\n \n\n\n\n\n\nTime:\n\n\n\n\n4:30 p.m. Eastern time (1:30 p.m. Pacific time)\n\n\n\n\n\n \n\n\n\n\n \n\n\n\n\n\nConference Call:\n\n\n\n\nDial (833) 540-1167 within the U.S.\n\n\n\n\n\n \n\n\n\n\nDial (929) 517-0358 outside the U.S.\n\n\n\n\n\n \n\n\n\n\nConference ID is 5486177\n\n\n\n\n\n \n\n\n\n\n \n\n\n\n\n\nWebcast:\n\n\n\n\nLive and replay webcast of the call are available here.\n\n\n\n\nAbout Ligand Pharmaceuticals\n\nLigand is a revenue-generating biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand’s business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand’s goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Ligand’s business model is based on doing what Ligand does best: drug discovery, early-stage drug development, product reformulation and partnering. Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory affairs and commercialization) to ultimately generate our revenue. Ligand’s OmniAb® technology platform is a patent-protected technology stack used in the discovery of fully human mono- and bispecific therapeutic antibodies. The Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optim...